Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 224,618	$ 287,496
Prepaid expenses and other current assets (including related party amounts of $0 and $82, respectively)	695	3,872
Total current assets	225,313	291,368
Property, plant and equipment, net	692	986
Operating lease right-of-use assets	2,031	2,373
Other long-term assets	341	384
Total assets	228,377	295,111
Current liabilities:
Accounts payable (including related party amounts of $311 and $173, respectively)	5,582	16,782
Accrued clinical trial expenses	10,491	19,997
Accrued expenses (including related party amounts of $1,847 and $734, respectively)	11,040	10,606
Accrued interest	214	312
Current portion of long-term debt		7,353
Operating lease liabilities, current	484	474
Total current liabilities	27,811	55,524
Long-term debt, net of discount	88,305	39,634
Operating lease liabilities	1,280	1,557
Other long-term liabilities	7,500	4,125
Total liabilities	124,896	100,840
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.0001 par value; authorized shares - 40,000,000 at September 30, 2021 and December 31, 2020 ; no shares issued and outstanding at September 30, 2021 and December 31, 2020
Common stock, $0.0001 par value; authorized shares — 400,000,000; issued shares — 31,414,827 and 31,262,769 at September 30, 2021 and December 31, 2020, respectively; outstanding shares — 30,047,428 and 28,516,010 at September 30, 2021 and December 31, 2020, respectively	3	3
Additional paid-in capital	597,022	579,755
Accumulated deficit	(493,544)	(385,487)
Total stockholders’ equity	103,481	194,271
Total liabilities and stockholders’ equity	$ 228,377	$ 295,111